Date: 14-Oct-2019

Innovent, Chi-Med expand global collaboration for solid tumor treatment

nnovent Biologics, Inc. and Hutchison China MediTech Limited (Chi-Med) have announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent's Tyvytģ (sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody, in combination with Chi-Med's surufatinib, a novel inhibitor of vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor 1 (FGFR1) and colony stimulating factor-1 receptor (CSF-1R), in patients with advanced solid tumors. The expansion builds on the existing global collaboration agreement between the two companies on sintilimab in combination with Chi-Med's highly selective VEGFR inhibitor, fruquintinib.